Passage Bio Statistics
Total Valuation
Passage Bio has a market cap or net worth of $19.91 million. The enterprise value is -$14.49 million.
Important Dates
The last earnings date was Tuesday, August 12, 2025, before market open.
Earnings Date | Aug 12, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Passage Bio has 3.12 million shares outstanding. The number of shares has increased by 7.82% in one year.
Current Share Class | 3.12M |
Shares Outstanding | 3.12M |
Shares Change (YoY) | +7.82% |
Shares Change (QoQ) | +2.04% |
Owned by Insiders (%) | 0.21% |
Owned by Institutions (%) | 46.16% |
Float | 2.81M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.46 |
P/TBV Ratio | 0.48 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.05, with a Debt / Equity ratio of 0.65.
Current Ratio | 3.05 |
Quick Ratio | 2.91 |
Debt / Equity | 0.65 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -88.27% and return on invested capital (ROIC) is -37.79%.
Return on Equity (ROE) | -88.27% |
Return on Assets (ROA) | -33.20% |
Return on Invested Capital (ROIC) | -37.79% |
Return on Capital Employed (ROCE) | -91.47% |
Revenue Per Employee | n/a |
Profits Per Employee | -$947,583 |
Employee Count | 60 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.72% in the last 52 weeks. The beta is 1.81, so Passage Bio's price volatility has been higher than the market average.
Beta (5Y) | 1.81 |
52-Week Price Change | -59.72% |
50-Day Moving Average | 7.18 |
200-Day Moving Average | 9.68 |
Relative Strength Index (RSI) | 50.25 |
Average Volume (20 Days) | 85,913 |
Short Selling Information
The latest short interest is 91,168, so 2.92% of the outstanding shares have been sold short.
Short Interest | 91,168 |
Short Previous Month | 108,282 |
Short % of Shares Out | 2.92% |
Short % of Float | 3.25% |
Short Ratio (days to cover) | 0.96 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -54.33M |
Pretax Income | -76.57M |
Net Income | -56.86M |
EBITDA | -52.49M |
EBIT | -54.33M |
Earnings Per Share (EPS) | -$18.35 |
Full Income Statement Balance Sheet
The company has $57.63 million in cash and $24.73 million in debt, giving a net cash position of $32.90 million or $10.54 per share.
Cash & Cash Equivalents | 57.63M |
Total Debt | 24.73M |
Net Cash | 32.90M |
Net Cash Per Share | $10.54 |
Equity (Book Value) | 38.26M |
Book Value Per Share | 12.07 |
Working Capital | 40.51M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$36.07 million and capital expenditures -$34,000, giving a free cash flow of -$36.10 million.
Operating Cash Flow | -36.07M |
Capital Expenditures | -34,000 |
Free Cash Flow | -36.10M |
FCF Per Share | -$11.57 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Passage Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -7.82% |
Shareholder Yield | -7.82% |
Earnings Yield | -308.83% |
FCF Yield | -196.10% |
Analyst Forecast
The average price target for Passage Bio is $140.00, which is 2,094.36% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $140.00 |
Price Target Difference | 2,094.36% |
Analyst Consensus | Strong Buy |
Analyst Count | 3 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:20.
Last Split Date | Jul 14, 2025 |
Split Type | Reverse |
Split Ratio | 1:20 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |